Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

HTAs published by Spanish Health Institute Carlos III in July 2022

On July 20, 2022, Health Institute Carlos III released two HTA reports.

One of the reports aimed to evaluate the effectiveness and safety of prophylactic or therapeutic use of additional anchoring systems for standard endoprostheses in endovascular aortic aneurysm repair procedures. The anchoring system considered in the report was Heli-FX™ EndoAnchor™ (Medtronic). It was concluded in the report that the data suggest that the use of Heli-FX™ EndoAnchor™ in endovascular aortic repair patients (prophylactically or as treatment of stent migrations or type I endoleaks) would be safe in medium-term follow-up for patients with unfavorable aneurysm neck anatomy, and probably safe in long-term follow-up for patients with favorable aneurysm neck anatomies. The evidence does not allow definitive conclusions on whether the use of anchors (endoanchors) represents an improvement in the endovascular aortic repair (including thoracic) procedures. Overall, the information collected on the critical outcome variables in terms of effectiveness would suggest the effectiveness of the device; however, the evidence is of very low quality. Results for most critical and important outcomes should be compared with treatments that do not include the Heli-FX™ EndoAnchor™ System in randomized controlled trials.

The report on the efficacy and safety of transanal irrigation (TAI) in adults with bowel dysfunction (BD) outlined that most studies found that TAI improves BD, regardless of the cause. However, the evidence is limited. Studies found that side effects are frequent, regardless of the clinical condition treated, but most were mild. However, assessing the relationship between TAI treatment and adverse events is difficult. The economic studies analyzed the cost-effectiveness of TAI in patients with neurogenic BD and estimated that the costs associated with the treatment would be lower than those of standard bowel care; however, these studies have methodological weaknesses. Further research on TAI is deemed essential.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.